Unrestrained activation of the JAK/STAT pathways in CD8+ T cells and keratinocytes contributes to vitiligo pathogenesis, making JAKs an attractive target for pharmacologic intervention in vitiligo treatment [39, 40]. Here, CD8A is linked to vitiligo.